Short communication: liver toxicity of lopinavir-containing regimens in HIV-infected patients with or without hepatitis C coinfection.
Liver toxicity is a common side effect of antiretroviral therapy, particularly in subjects coinfected with the hepatitis C virus (HCV). The incidence of severe liver toxicity after initiation of treatment with lopinavir (LPV) as well as its possible association with LPV plasma levels were assessed in 120 HIV-infected patients (52% coinfected by HCV). The incidence of severe liver toxicity at 3 months was 1.7% and the cumulative incidence at 12 months was 4%. The development of severe liver toxicity was associated with HCV coinfection but not with LPV plasma levels.
González-Requena
Daniel
D
Service of Infectious Diseases and Pharmacy Unit, Hospital Carlos III, 28035 Madrid, Spain.
Núñez
Marina
M
Jiménez-Nacher
Inmaculada
I
González-Lahoz
Juan
J
Soriano
Vincent
V
D000328:Adult; D019380:Anti-HIV Agents / Q000633:toxicity*; D018791:CD4 Lymphocyte Count; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D006526:Hepatitis C / Q000150:complications* / Q000473:pathology; D006801:Humans; D015994:Incidence; D008099:Liver / Q000187:drug effects / Q000473:pathology* / Q000821:virology; D061466:Lopinavir; D008297:Male; D011744:Pyrimidinones / Q000633:toxicity*
D019380:Anti-HIV Agents; D011744:Pyrimidinones; D061466:Lopinavir